JP2018064560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018064560A5 JP2018064560A5 JP2017213749A JP2017213749A JP2018064560A5 JP 2018064560 A5 JP2018064560 A5 JP 2018064560A5 JP 2017213749 A JP2017213749 A JP 2017213749A JP 2017213749 A JP2017213749 A JP 2017213749A JP 2018064560 A5 JP2018064560 A5 JP 2018064560A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- fragment
- framework
- antibody antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 19
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 claims 10
- 102100022243 Transmembrane emp24 domain-containing protein 1 Human genes 0.000 claims 10
- 210000003630 histaminocyte Anatomy 0.000 claims 6
- 230000036755 cellular response Effects 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 108010067003 Interleukin-33 Proteins 0.000 claims 4
- 102000017761 Interleukin-33 Human genes 0.000 claims 4
- 238000010494 dissociation reaction Methods 0.000 claims 4
- 230000005593 dissociations Effects 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 102000055002 human IL1RL1 Human genes 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 claims 2
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 claims 2
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010052568 Urticaria chronic Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 208000024376 chronic urticaria Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 210000002175 goblet cell Anatomy 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 210000004969 inflammatory cell Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000008719 thickening Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000998949 Homo sapiens Immunoglobulin heavy variable 1-24 Proteins 0.000 claims 1
- 101000989058 Homo sapiens Immunoglobulin heavy variable 1-69-2 Proteins 0.000 claims 1
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims 1
- 101001138123 Homo sapiens Immunoglobulin kappa variable 1-27 Proteins 0.000 claims 1
- 101001138121 Homo sapiens Immunoglobulin kappa variable 1-33 Proteins 0.000 claims 1
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 claims 1
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims 1
- 101001138130 Homo sapiens Immunoglobulin kappa variable 1-9 Proteins 0.000 claims 1
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims 1
- 102100036890 Immunoglobulin heavy variable 1-24 Human genes 0.000 claims 1
- 102100029422 Immunoglobulin heavy variable 1-69-2 Human genes 0.000 claims 1
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims 1
- 102100020902 Immunoglobulin kappa variable 1-27 Human genes 0.000 claims 1
- 102100020901 Immunoglobulin kappa variable 1-33 Human genes 0.000 claims 1
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 claims 1
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims 1
- 102100020770 Immunoglobulin kappa variable 1-9 Human genes 0.000 claims 1
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 230000006041 cell recruitment Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640407P | 2012-04-30 | 2012-04-30 | |
| US201261640238P | 2012-04-30 | 2012-04-30 | |
| US61/640,238 | 2012-04-30 | ||
| US61/640,407 | 2012-04-30 | ||
| US13/798,226 US9212227B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| US13/798,226 | 2013-03-13 | ||
| US13/798,204 US9090694B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists |
| US13/798,204 | 2013-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510362A Division JP6283354B2 (ja) | 2012-04-30 | 2013-04-29 | Ｓｔ２ｌ拮抗物質及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019097226A Division JP2019162136A (ja) | 2012-04-30 | 2019-05-24 | Ｓｔ２ｌ拮抗物質及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018064560A JP2018064560A (ja) | 2018-04-26 |
| JP2018064560A5 true JP2018064560A5 (enExample) | 2018-09-27 |
| JP6622274B2 JP6622274B2 (ja) | 2019-12-18 |
Family
ID=49477497
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510362A Expired - Fee Related JP6283354B2 (ja) | 2012-04-30 | 2013-04-29 | Ｓｔ２ｌ拮抗物質及び使用方法 |
| JP2017213749A Expired - Fee Related JP6622274B2 (ja) | 2012-04-30 | 2017-11-06 | Ｓｔ２ｌ拮抗物質及び使用方法 |
| JP2019097226A Withdrawn JP2019162136A (ja) | 2012-04-30 | 2019-05-24 | Ｓｔ２ｌ拮抗物質及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510362A Expired - Fee Related JP6283354B2 (ja) | 2012-04-30 | 2013-04-29 | Ｓｔ２ｌ拮抗物質及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019097226A Withdrawn JP2019162136A (ja) | 2012-04-30 | 2019-05-24 | Ｓｔ２ｌ拮抗物質及び使用方法 |
Country Status (37)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−３３拮抗薬とその使用法 |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| US9631024B2 (en) | 2014-06-23 | 2017-04-25 | Bionomics, Inc. | Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| WO2016140921A1 (en) * | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| AU2017208099A1 (en) * | 2016-01-14 | 2018-08-09 | Anaptysbio, Inc. | Inhibition of allergic reaction using an IL-33 inhibitor |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN116715775A (zh) | 2017-02-10 | 2023-09-08 | 豪夫迈·罗氏有限公司 | 抗类胰蛋白酶抗体、其组合物及其用途 |
| WO2018178076A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| PE20201149A1 (es) | 2017-12-21 | 2020-10-26 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1 |
| KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| IL307286B2 (en) | 2018-04-11 | 2026-03-01 | Regeneron Pharma | Methods and compositions for quantifying il-33 |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | 迈威(上海)生物科技有限公司 | 用于测定人il-33/st2通路抑制剂的生物学活性的方法 |
| JP7843701B2 (ja) | 2019-11-04 | 2026-04-10 | メディミューン リミテッド | Ｉｌ－３３アンタゴニストの使用方法 |
| KR20220092927A (ko) | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | 신장 장애를 치료하기 위한 항 il-33 치료제 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| JP2023516497A (ja) | 2020-03-13 | 2023-04-19 | メドイミューン・リミテッド | Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法 |
| CN115867575A (zh) | 2020-04-06 | 2023-03-28 | 免疫医疗有限公司 | 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征 |
| CN121914272A (zh) * | 2020-05-12 | 2026-04-24 | 正大天晴药业集团股份有限公司 | St2抗原结合蛋白 |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| CA3217279A1 (en) | 2021-05-04 | 2022-11-10 | Olga Ignatovich | Anti-tigit antibodies and methods of use thereof |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN119183384A (zh) * | 2022-02-24 | 2024-12-24 | 中国抗体制药有限公司 | 针对警报素的双特异性结合蛋白及其用途 |
| CN115838425B (zh) * | 2022-08-31 | 2024-06-18 | 首都医科大学 | 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用 |
| US12054552B2 (en) | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
| CN119841936B (zh) * | 2024-12-30 | 2025-09-30 | 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) | 抗非洲猪瘟病毒p72蛋白中和性单克隆抗体5d2及其应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6103529A (en) | 1996-10-10 | 2000-08-15 | Life Technologies, Inc. | Animal cell culture media comprising peptides derived from rice |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1355919B1 (en) * | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6649055B1 (en) | 2002-05-07 | 2003-11-18 | The United States Of America As Represented By The United States Department Of Energy | Pump station for radioactive waste water |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| JP2007522118A (ja) * | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CA2587627A1 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CA2661023C (en) | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| JP2010527936A (ja) * | 2007-05-18 | 2010-08-19 | メディミューン，エルエルシー | 炎症性疾患におけるｉｌ−３３ |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| US8817596B2 (en) | 2009-01-09 | 2014-08-26 | Futurewei Technologies, Inc. | Protecting ingress and egress of a label switched path |
| US7879978B2 (en) * | 2009-03-31 | 2011-02-01 | Centocor Ortho Biotech, Inc. | Macaca fascicularis ST2L |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| PL2552961T3 (pl) | 2010-03-30 | 2018-04-30 | Janssen Biotech, Inc. | Humanizowane przeciwciała il-25 |
| RU2684724C2 (ru) | 2010-04-09 | 2019-04-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| EP2621950A4 (en) | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | ANTIBODIES FOR BINDING HUMAN COLLAGEN II |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| ES2549637T3 (es) | 2011-02-23 | 2015-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL33R humano y la utilización de los mismos |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
-
2013
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko not_active Expired - Fee Related
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 SM SM20190639T patent/SMT201900639T1/it unknown
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en not_active Ceased
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active Withdrawn
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
-
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
-
2015
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
-
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191884T1 (hr) | St2l antagonisti i postupci upotrebe | |
| AU2023203440A1 (en) | Antibodies that specifically bind to TL1A | |
| AU2008300028B2 (en) | Antigen binding proteins capable of binding thymic stromal lymphopoietin | |
| JP2018521691A5 (enExample) | ||
| JP2019500893A5 (enExample) | ||
| JP2021513974A5 (enExample) | ||
| JP2016538876A5 (enExample) | ||
| JP2011501945A5 (enExample) | ||
| JP2009523154A5 (enExample) | ||
| JP2008527989A5 (enExample) | ||
| JP2014503209A5 (enExample) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2020511946A5 (enExample) | ||
| JP2018516537A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2018519364A5 (enExample) | ||
| JP2008511542A5 (enExample) | ||
| RU2013123927A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173 | |
| JP2014508511A5 (enExample) | ||
| JP2015502915A5 (enExample) | ||
| HRP20131167T1 (hr) | Antitijela za humani receptor programirane smrti pd-1 | |
| HRP20192052T1 (hr) | Protutijela anti-siglec-8 te njihovi postupci i uporabe | |
| JP2009533020A5 (enExample) | ||
| RU2018124307A (ru) | Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции | |
| JP2012522531A5 (enExample) |